Investigational Subcutaneous Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Ulcerative Colitis
(WorldNews Japan)

Takeda Pharmaceutical Company Limited [TSE:4502] (`Takeda`) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab for maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC) who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) induction therapy. At week 52, a statistically significant proportion of patients receiving vedolizumab SC achieved clinical remission** compared to patients receiving placebo (46.2% vs. 14.3%; p1 These results were presented at the 2018...